ERBB2 and breast cancer: In this context, those exhibiting HER2-low expression might represent ideal candidates for the inclusion in ongoing clinical trials of anti-HER2 ADCs and, more importantly, in case these emerging strategies were to become available for HER2-low BC in the near future.